CUE BIOPHARMA INC (CUE) Stock Price, Forecast & Analysis
USA - NASDAQ:CUE - US22978P1066 - Common Stock
CUE Key Statistics, Chart & Performance
The current stock price of CUE is 0.7012 USD. In the past month the price decreased by -11.85%. In the past year, price decreased by -59.23%.
CUE Latest News, Press Relases and Analysis
CUE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About CUE
Company Profile
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. The company is headquartered in Boston, Massachusetts and currently employs 41 full-time employees. The company went IPO on 2018-01-02. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.
Company Info
CUE BIOPHARMA INC
40 Guest Street
Boston MASSACHUSETTS 02139 US
CEO: Daniel R. Passeri
Employees: 41
Phone: 16179492680
CUE BIOPHARMA INC / CUE FAQ
What does CUE do?
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. The company is headquartered in Boston, Massachusetts and currently employs 41 full-time employees. The company went IPO on 2018-01-02. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.
What is the stock price of CUE BIOPHARMA INC today?
The current stock price of CUE is 0.7012 USD. The price decreased by -2.05% in the last trading session.
Does CUE stock pay dividends?
CUE does not pay a dividend.
How is the ChartMill rating for CUE BIOPHARMA INC?
CUE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the number of employees for CUE BIOPHARMA INC?
CUE BIOPHARMA INC (CUE) currently has 41 employees.
Can you provide the ownership details for CUE stock?
You can find the ownership structure of CUE BIOPHARMA INC (CUE) on the Ownership tab.
CUE Technical Analysis
CUE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CUE. CUE may be in some trouble as it scores bad on both profitability and health.
CUE Financial Highlights
Over the last trailing twelve months CUE reported a non-GAAP Earnings per Share(EPS) of -0.56. The EPS increased by 42.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -95.55% | ||
| ROE | -214.19% | ||
| Debt/Equity | 0.01 |
CUE Forecast & Estimates
7 analysts have analysed CUE and the average price target is 4.08 USD. This implies a price increase of 481.86% is expected in the next year compared to the current price of 0.7012.
For the next year, analysts expect an EPS growth of 42.09% and a revenue growth -21.59% for CUE